Method for Assaying Peritonitis in Humans

Simple SummaryContent extracted from patent full text and abstract with AI.

The patent discloses a method for predicting and diagnosing infectious peritonitis in humans by measuring the level of pancreatic stone protein/regenerating protein (PSP/reg) in serum or plasma. Elevated levels of PSP/reg are used as biomarkers to indicate the presence, risk, and severity of peritonitis, enabling patient risk classification and outcome prediction. The method utilizes common laboratory techniques such as ELISA and can aid in early detection and management of intra-abdominal infections.

Use CasesContent extracted from patent full text and abstract with AI.

• Early diagnosis of infectious peritonitis in hospital or ICU settings.
• Risk stratification of patients with suspected abdominal infections.
• Monitoring postoperative patients for signs of intra-abdominal infection or sepsis.
• Guiding clinical decisions regarding need for intensive care, antibiotic therapy, or additional surgery.
• Predicting outcomes and mortality risk in peritonitis patients to tailor treatment plans.
• Developing commercial diagnostic kits for hospital laboratories to rapidly assess PSP/reg.
• Non-invasive or minimally invasive screening for intra-abdominal infectious complications, reducing reliance on paracentesis.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables rapid and reliable diagnosis of peritonitis using blood samples rather than more invasive procedures like paracentesis.
• Early detection allows for timely intervention, potentially decreasing morbidity and mortality.
• Can distinguish between local and diffuse infections, improving treatment accuracy.
• PSP/reg levels provide a quantitative and objective marker correlated with disease severity and risk of organ failure.
• Supports personalized patient management by enabling risk stratification and outcome prediction.
• Reduces time, labor, and resources needed for current diagnostic methods.
• Potential for use in widely available diagnostic platforms like ELISA, facilitating broad clinical adoption.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a reliable method of prediction of infectious peritonitis in humans, wherein the level of pancreatic stone protein / regenerating protein (PSP/reg) is determined in serum or plasma, and a high level is indicative of the development and the severity of peritonitis, allowing the classification of patients according to risk.